Quetiapine
Seroquel (quetiapine) is a small molecule pharmaceutical. Quetiapine was first approved as Seroquel on 1997-09-26. It is used to treat autistic disorder, bipolar disorder, major depressive disorder, psychotic disorders, and schizophrenia amongst others in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A and D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1D, 5-hydroxytryptamine receptor 1F, sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 1A, histamine H1 receptor, and 5-hydroxytryptamine receptor 1E.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Seroquel (generic drugs available since 2012-03-27)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| quetiapine fumarate | ANDA | 2023-06-20 |
| seroquel | New Drug Application | 2022-04-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| autistic disorder | EFO_0003758 | D001321 | F84.0 |
| bipolar disorder | EFO_0000289 | D001714 | F30.9 |
| major depressive disorder | EFO_0003761 | D003865 | F22 |
| psychotic disorders | — | D011618 | F20.81 |
| schizophrenia | EFO_0000692 | D012559 | F20 |
| schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
351 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 9 | 7 | 40 | 47 | 11 | 111 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 2 | 3 | 30 | 26 | 14 | 74 |
| Psychotic disorders | D011618 | F20.81 | 2 | 2 | 10 | 18 | 5 | 36 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 5 | 15 | 5 | 5 | 30 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 9 | 6 | 3 | 18 |
| Depression | D003863 | F33.9 | 1 | — | 5 | 4 | 2 | 12 | |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 4 | 3 | 4 | — | 11 |
| Healthy volunteers/patients | — | 7 | — | — | 2 | — | 9 | ||
| Delirium | D003693 | R41.0 | 2 | 2 | 5 | 1 | 1 | 9 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | 1 | 6 | 1 | 8 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | 2 | — | — | 3 |
| Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | 1 | 2 | — | — | 3 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Sleep | D012890 | GO_0030431 | — | — | 1 | — | — | 1 | |
| Cognition | D003071 | EFO_0003925 | — | — | 1 | — | — | 1 | |
| Vascular dementia | D015140 | F01 | — | — | 1 | — | — | 1 | |
| Tic disorders | D013981 | F95 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | 1 | — | — | 1 | 2 |
| Marijuana smoking | D008385 | — | 1 | — | — | — | 1 | ||
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 1 | — | — | — | 1 |
| Alcohol drinking | D000428 | EFO_0004329 | — | 1 | — | — | — | 1 | |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | 1 | — | — | — | 1 | 2 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 1 | — | — | — | — | 1 |
| Hypercapnia | D006935 | 1 | — | — | — | — | 1 | ||
| Drug-induced dyskinesia | D004409 | EFO_1000904 | 1 | — | — | — | — | 1 | |
| Chronic renal insufficiency | D051436 | N18 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | — | 1 | 1 | ||
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | — | 1 | 1 |
| Dysthymic disorder | D019263 | EFO_0008623 | F34.1 | — | — | — | — | 1 | 1 |
| Dissociative disorders | D004213 | F44.1 | — | — | — | — | 1 | 1 | |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | 1 | 1 | |
| Regional blood flow | D012039 | — | — | — | — | 1 | 1 | ||
| Ocular physiological phenomena | D009799 | — | — | — | — | 1 | 1 | ||
| Sepsis-associated encephalopathy | D065166 | G93.41 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | QUETIAPINE |
| INN | quetiapine |
| Description | Quetiapine is a dibenzothiazepine, a N-alkylpiperazine and a N-arylpiperazine. It has a role as a serotonergic antagonist, a dopaminergic antagonist, a histamine antagonist, an adrenergic antagonist and a second generation antipsychotic. |
| Classification | Small molecule |
| Drug class | tricyclic compounds; antipsychotics (dibenzothiazepine derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 111974-69-7 |
| RxCUI | 51272 |
| ChEMBL ID | CHEMBL716 |
| ChEBI ID | 8707 |
| PubChem CID | 5002 |
| DrugBank | DB01224 |
| UNII ID | BGL0JSY5SI (ChemIDplus, GSRS) |
Target
Agency Approved
HTR2A
HTR2A
DRD2
DRD2
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Alternate
HTR1D
HTR1D
HTR1F
HTR1F
SLC6A2
SLC6A2
HTR1A
HTR1A
HRH1
HRH1
HTR1E
HTR1E
Organism
Homo sapiens
Gene name
HTR1D
Gene synonyms
HTR1DA, HTRL
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1D
Protein synonyms
5-HT-1D, 5-HT-1D-alpha, 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled, Serotonin 1D alpha receptor, Serotonin receptor 1D
Uniprot ID
Mouse ortholog
Htr1d (15552)
5-hydroxytryptamine receptor 1D (Q8BUW7)
Variants
Clinical Variant
No data
Financial
Seroquel - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,127 documents
View more details
Safety
Black-box Warning
Black-box warning for: Quetiapine fumarate, Seroquel
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,184 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more